News Summary
NegativeAcadia Healthcare delivered a Q2 2026 earnings beat (+15% EPS surprise) with revenue exceeding expectations, and the stock has surged 96% YTD as of early October 2026 following CEO Debra Osteen's return in January. However, this recovery masks significant legal headwinds, including a $105 million California jury verdict against a subsidiary, ongoing derivative and securities lawsuits, and analyst downgrades citing slower top-line growth and reserve cost pressures.
Red flags
- •$105 million employment lawsuit verdict against Acadia subsidiary (California jury)
- •Derivative settlement with preliminary court approval (Sept 2026) indicating governance/fiduciary duty concerns
- •Securities lawsuit proceeding after dismissal denial (July 2026)
- •Multiple ongoing law firm investigations into officer/director breach of fiduciary duties through Aug–Sept 2026
- •Q2 same-facility revenue flat with revenue per patient day declining despite patient day growth
- •Raymond James downgrade to Outperform from Strong Buy (late Sept 2026)
- •Stock declined post-earnings despite beat, signaling investor concern over growth trajectory and reserve costs
- •Company added to Russell 2000 (June 27, 2026), indicating loss of large-cap status
Funds Reducing / Exiting (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 0 | −1.3M | — | 0.4% | -100% | EXITED |
| Soros Fund Management | Soros Family Office | 0 | −23K | — | <0.1% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −537K | — | <0.1% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 3 | 1.63 | -2.6% |
| Q1 2026 | LONG | 4 | 3.63 | +12.1% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Dimensional Fund Advisors LP | SC 13G | 4.7M | 5.0% | 2026-10-08 | ↗ |
| Khrom Investments Fund, LP | SC 13G/A | 647K | 0.7% | 2026-08-14 | ↗ |
| Wellington Management Group LLP | SC 13G/A | 5.7M | 6.2% | 2026-08-13 | ↗ |
| FMR LLC | SC 13G/A | 5.0M | 5.5% | 2026-08-06 | ↗ |
| BlackRock, Inc. | SC 13G/A | 13.8M | 15.0% | 2026-07-27 | ↗ |
| Khrom Investments Fund, LP | SC 13G/A | 5.2M | 5.7% | 2026-05-15 | ↗ |
| Wellington Management Group LLP | SC 13G/A | 9.1M | 9.9% | 2026-05-15 | ↗ |
| THE GOLDMAN SACHS GROUP, INC. | SC 13G/A | 1.5M | 1.6% | 2026-05-11 | ↗ |
| Vanguard Capital Management | SC 13G | 4.8M | 5.3% | 2026-04-29 | ↗ |
| Vanguard Portfolio Management | SC 13G | 5.1M | 5.5% | 2026-04-28 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.